ARS Pharmaceuticals (SPRY) Short-term Investments (2022 - 2026)

ARS Pharmaceuticals has disclosed Short-term Investments across 5 years of filings, most recently posting $176.6 million for Q1 2026.

• Short-term Investments for Q1 2026 came in at $176.6 million, down 25.11% year-over-year; the trailing twelve-month figure through Mar 2026 was $176.6 million (down 25.11% YoY), and the FY2025 annual result was $203.7 million, down 22.62% from the prior year.
• Short-term Investments came in at $176.6 million for Q1 2026 at ARS Pharmaceuticals, down from $203.7 million in the prior quarter.
• In the past five years, Short-term Investments ranged from a high of $263.2 million in Q4 2024 to a low of $19.9 million in Q1 2022.
• The 5-year median for Short-term Investments is $176.6 million (2026), against an average of $155.7 million.
• Across the five-year window, Short-term Investments surged 789.75% in 2023 and decreased 25.11% in 2026, its largest moves.
• ARS Pharmaceuticals' Short-term Investments stood at $63.9 million in 2022, then soared by 146.45% to $157.4 million in 2023, then jumped by 67.23% to $263.2 million in 2024, then declined by 22.62% to $203.7 million in 2025, then decreased by 13.27% to $176.6 million in 2026.
• The last three Short-term Investments figures came in at $176.6 million (Q1 2026), $203.7 million (Q4 2025), and $228.7 million (Q3 2025), per Business Quant data.